news
Customising T cell-based immunotherapies to treat cancers
US researchers usings a ‘SNAP’ receptor system can customise immunotherapies for targeted treatments of cancer and other diseases.
List view / Grid view
Immuno-oncology
news
Analysis of 33 tumour types identifies new immunotherapy targets
The researchers identified 1,068 transposable element-derived transcripts with the potential to produce tumour antigens that could serve as targets for new immunotherapies.
webinar
Accelerating biologics discovery via antibody library and reaching IND faster with cell line development
4 April 2023 | By GenScript ProBio
The application of Fab and VHH naïve library to expedite the antibody discovery against tumor-associated antigen for CAR-T, ADC and bispecific antibody.
news
Ground-breaking glycocalyx study could improve cancer immunotherapy
The researchers found that cancer cells with thicker glycocalyx barrier are better at evading immune cells.
whitepaper
Whitepaper: Serum-free and Animal-free Research
Discover how the adoption of animal-free media/supplements can improve reproducibility in cell culture and biotherapeutic research.
whitepaper
Whitepaper: PSMA Protein in the Battle Against Cancer
The PSMA Protein is a new therapeutic hot target. In this article, learn about its growing role in the fight against prostate cancer and beyond.
news
Stopping immune cell leakage from tumours could improve skin cancer treatment
Results show the number of specialised immune cells available for fighting skin cancer doubled when a new treatment blocked their escape from melanoma tumours.
article
Transforming the way cancer vaccines are designed and made
Researchers found that ‘rational vaccinology’ increases potency by changing the structural location of antigens and adjuvants.
news
Discovery of CAFs’ origin gives new direction for pancreatic cancer
US researchers discovered a type of cell involved it pancreatic cancer and sheds light on the origin of cancer-associated fibroblasts (CAFs).
article
Developing state-of‑the‑art CAR T-cell therapy for cancer treatment
In this Q&A, Dr Frank Neumann speaks about Kite Pharma’s work with chimeric antigen receptor (CAR) T-cell therapy and how the company is working to progress this next‑generation modality even further to help treat cancer patients.
article
Allogeneic CAR T-cell therapy: the future of cancer care
In this Q&A, Dr Devon Shedlock discusses Poseida Therapeutics' cancer treatment pipeline and the advances it has made towards developing chimeric antigen receptor (CAR) T-cell therapies for liquid and solid tumours.
article
The next wave: going beyond CAR T cells with cell-based therapies
In this article, Dr Daniel Teper and Dr Chris Arendt explore cellular therapies for cancer that provide an alternative to chimeric antigen receptor (CAR) T-cell therapy. In these Q&As, they outline their important work in immuno-oncology.
article
The advantages of gamma-delta T-cell therapy
Here, Dr Michael Leek describes the benefits of gamma-delta T cells for cancer therapy, exploring why they present a potential alternative to other immuno-oncology platforms.
article
When exhausted, cancer-fighting T cells may switch sides
Using flow cytometry, Dr Greg Delgoffe and Dr Paolo Vignali highlight that low oxygen environment of tumours can prompt exhausted T cells to suppress the immune system instead of combating cancer.
article
Five recent cell and gene therapy discoveries
This article highlights five of the latest findings using cell and gene therapy techniques that could be used in the development or design of new therapies.
